Biochemical and Biophysical Research Communications, Vol.517, No.2, 201-209, 2019
EZH2 regulates PD-L1 expression via HIF-1 alpha in non-small cell lung cancer cells
Lung cancer is the most commonly diagnosed cancer and accounts for most cancer-related mortalities worldwide. The high expression of programmed death ligand 1 (PD-L1) is an important factor that promotes immune escape of lung cancer, thus aggravates chemotherapy resistance and poor prognosis. Therefore, understanding the regulatory mechanism of PD-L1 in lung cancer is critical for tumor immunotherapy. Enhancer of Zeste homolog2 (EZH2), an epigenetic regulatory molecule with histone methyltransferase activity, promotes the formation of an immunosuppressive microenvironment. This study aimed to investigate the role of EZH2 in PD-L1 expression and in the progression of lung tumors. We found that EZH2 was upregulated in lung cancer tissues and positively correlated with PD-L1 levels and poor prognosis. Further, shRNA-expressing lentivirus mediated EZH2 knockdown suppressed both the mRNA and protein expression level of PD-L1, thus delaying lung cancer progression in vivo by enhancing anti-tumor immune responses. Moreover, the regulatory effect of EZH2 on PD-Ll depended on HIF-1 alpha. The present results indicate that EZH2 regulates the immunosuppressive molecule PD-Ll expression via HIF-1 alpha in non-small cell lung cancer cells. (C) 2019 The Authors. Published by Elsevier Inc.